Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)

• Status: Completed
• Trial end date: 2002-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Guanfacine

Criteria

• Males and females, age 18-65

• Diagnosis of PTSD from combat or civilian trauma

• No major medical problems such as diabetes, cardiovascular disease

• Taking no psychiatric medication, or taking only one SSRI antidepressant